Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients

International Journal of Cardiology

Volumn 172, Issue 2, 2014, Pages 332-339

  Simonneau, Gérald ^a   Galiè, Nazzareno ^b   Jansa, Pavel ^c   Meyer, Gisela Martina Bohns ^d   Al Hiti, Hikmet ^e   Kusic Pajic, Andjela ^f   Lemarié, Jean Christophe ^g   Hoeper, Marius M ^h   Rubin, Lewis J ⁱ  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Complexo Hospitalar Sta Casa de Porto Alegre ^*  (Brazil)

^e INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^f ACTELION PHARMACEUTICALS LTD   (Switzerland)

^g Effi Stat   (France)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bosentan; Endothelin; Pulmonary arterial hypertension; Risk factors; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ASPARTATE AMINOTRANSFERASE; BOSENTAN; ANTIHYPERTENSIVE AGENT; SULFONAMIDE;

6 MINUTE WALK DISTANCE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CLINICAL STUDY; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIN ANTAGONIST TRIAL IN MILDLY STUDY; EVENT FREE SURVIVAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS; HEPATITIS C; HUMAN; HYPERTRANSAMINASEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OXYGEN SATURATION; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SUDDEN DEATH; SURVIVAL RATE; TOXIC HEPATITIS; WORLD HEALTH ORGANIZATION FUNCTIONAL CLASS; DOUBLE BLIND PROCEDURE; EXERCISE TEST; HYPERTENSION, PULMONARY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RISK FACTORS; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84900584030     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.12.179     Document Type: Article

References (20)

1. R.T. Schermuly, H.A. Ghofrani, M.R. Wilkins, and F. Grimminger Mechanisms of disease: pulmonary arterial hypertension Nat Rev Cardiol 8 2011 443 455
2. L.S. Howard Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease Eur Respir Rev 20 2011 236 242
3. M. Humbert, O. Sitbon, and A. Chaouat et al. Pulmonary arterial hypertension in France: results from a national registry Am J Respir Crit Care Med 173 2006 1023 1030
4. O. Sitbon, and N. Galiè Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals Eur Respir Rev 19 2010 272 278
5. O. Sitbon, M. Humbert, and H. Nunes et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788
6. D. Launay, O. Sitbon, and J. Le Pavec et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil Rheumatology 49 2010 490 500
7. N. Nickel, H. Golpon, and M. Greer et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension Eur Respir 39 2012 589 596
8. N. Galiè, L.J. Rubin, and M. Hoeper et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial Lancet 371 2008 2093 2100
9. V.V. McLaughlin, O. Sitbon, and D.B. Badesch et al. Survival with first-line bosentan in patients with primary pulmonary hypertension Eur Respir J 25 2005 244 249
10. Actelion Pharmaceuticals Ltd Tracleer® (bosentan) EU summary of product characteristics 2012 Actelion Phamaceutials Ltd. Allschwil, Switzerland
11. G.E. D'Alonzo, R.J. Barst, and S.M. Ayres et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 1991 343 349
12. L.J. Rubin, D.B. Badesch, and T.R. Fleming et al. SUPER-2 Study Group. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study Chest 140 2011 1274 1283
13. R.L. Benza, M. Gomberg-Maitland, and D.P. Miller et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension Chest 141 2012 354 362
14. R.L. Benza, D.P. Miller, and M. Gomberg-Maitland et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Circulation 122 2010 164 172
15. N. Nagaya, T. Nishikimi, and M. Uematsu et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension Circulation 102 2000 865 870
16. A. Fijalkowska, M. Kurzyna, and A. Torbicki et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension Chest 129 2006 1313 1321
17. M. Humbert, O. Sitbon, and A. Chaouat et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era Circulation 122 2010 156 163
18. L. Chung, J. Liu, and L. Parsons et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype Chest 138 2010 1383 1394
19. N. Galiè, M.M. Hoeper, and M. Humbert et al. ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
20. R.J. Oudiz, N. Galiè, and H. Olschewski et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension J Am Coll Cardiol 54 2009 1971 1981